Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Homegrown Competition Looming
Executive Summary
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.